Company news
Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A (SSE:603811) news
Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: "Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Announcement…
Press releases & updates
"Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Announcement on a Subsidiary's Receipt of Drug GMP Compliance Inspection Results
September 28, 2026
"Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Announcement on Outline of the 2026 Semi-annual Performance Briefing
September 17, 2026
"Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Announcement on Satisfaction of Unlocking Conditions for the 1st Unlocking Period under the 2025 Employee Stock Ownership Plan
September 15, 2026
"Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
September 10, 2026
"Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Announcement on Resolutions of the 6th Meeting of the 5th Board of Directors
August 26, 2026
"Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Announcement on Shareholding Reduction Plan for Directors and Senior Management Members
June 30, 2026
Announcement on Progress in Providing Guarantee for Subsidiary
June 22, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 18, 2026
Announcement on Results of GMP Compliance Inspection Concerning Drugs
June 4, 2026
Announcement on Outline of the Performance Briefing for 2025 and Q1 2026
May 22, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 19, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 14, 2026
Announcement on Remunerations for Directors and Senior Management Members in 2025 and 2026 Remuneration Plan
April 23, 2026
Announcement on Selection of Products for Continuation Procurement Under National Procurement Scheme After Agreement Expiry
February 10, 2026
Announcement on the Acquisition of Drug Registration Certificate for Torasemide Tablets
December 9, 2025
Announcement on Progress in Providing Guarantee
December 2, 2025
Announcement on Completing Shareholding Reduction Plan for Person Acting in Concert of Controlling Shareholder and the Results of Shareholding Reduction
November 26, 2025
Indicative Announcement on Change in Equity of Controlling Shareholders and Persons Acting in Concert Reaching 1% Scale
November 14, 2025
Report for Q3 2025
October 27, 2025
Announcement on Completion of the Government’s Compensatory Recovery of Land and Associated Assets of Subsidiaries
October 13, 2025
Announcement on Shareholding Reduction Plan for Person Acting in Concert of Controlling Shareholder
September 19, 2025
Announcement on Outline of the 2025 Semi-annual Performance Briefing
September 18, 2025
Announcement on Completion of Non-trading Transfer under the 2025 Employee Stock Ownership Plan
September 17, 2025
Announcement on Resolutions of the 1st Holders' Meeting for 2025 Employee Stock Ownership Plan
September 16, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 15, 2025
Announcement on the Company's Drug Passing Consistency Evaluation of Generic Drug
September 12, 2025
Announcement on Obtainment of Drug Registration Certificate for Icosapent Ethyl Soft Capsules
September 1, 2025
Announcement on Appointment of Deputy General Manager
August 26, 2025
Announcement on Retirement and Resignation of Senior Management Member
August 18, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
August 11, 2025
Announcement on Abnormal Fluctuations in Stock Trading
August 6, 2025
Announcement on Progress in Repurchasing Shares through Call Auction
August 4, 2025
Announcement on the Acquisition of Drug Registration Certificate for Peramivir Injection
July 31, 2025
Semi-annual Earnings Preannouncement for 2025
July 13, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 11, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
June 4, 2025
Announcement on Election of Employee Director for the 5th Board of Directors
May 20, 2025
Report for Q1 2025
April 29, 2025
Announcement on the Acquisition of Drug Registration Certificate for Mercaptopurine Tablets
April 14, 2025
Announcement on Obtaining Australia's TGA-GMP Certificate
January 10, 2025
Announcement on the Acquisition of Drug Registration Certificate for Calcitriol Soft Capsules
January 2, 2025
Announcement on Progress in Repurchasing 2% of Shares through Call Auction
December 23, 2024
Announcement on Outline of the Q3 2024 Performance Briefing
November 18, 2024
Announcement on Resolution of the 2nd Extraordinary General Meeting in 2024
November 13, 2024
Announcement on Obtaining Share Repurchase Loans from Financial Institutions
November 7, 2024
Report for Q3 2024
October 28, 2024